Benzothiazole-Based Cycloplatinated Chromophores: Synthetic, Optical, and Biological Studies

Ladder-like heteropolynuclear assemblies via cyanido bridges and platinum(II)-thallium(I) bonds: structural and photophysical properties

We describe the mononuclear anionic cyanido-pentafluorophenyl complexes, (NBu4)[Pt(C^N)(C6F5)(CN)] [C^N = 7,8-benzoquinolate (bzq) 1, 2-(2,4-difluorophenyl)pyridinate (dfppy) 2] and the heteropolynuclear derivatives [{Pt(C^N)(C6F5)(CN)}Tl] (C^N = bzq 3, dfppy 4). These complexes were synthesized via a two-step modular synthesis by reaction of the corresponding potassium salts K[Pt(C^N)(C6F5)(CN)], prepared in situ from [Pt(C^N)(C6F5)(DMSO)] and KCN in acetone/H2O, with TlPF6. The structures of {[Pt(bzq)(C6F5)(CN)Tl]·THF}n (3·THF)n and [{Pt(dfppy)(C6F5)(CN)}Tl]4·dioxane [4]4·dioxane, determined by X-ray crystallography, confirm the presence of Pt(II)-Tl(I) bonds [2.9795(6)-3.0736(3) Å], but in the dfppy complex, the incorporation of dioxane, causes a significant structural change. Thus, whereas [3·THF]n achieves a bent-ladder shape extended double chain Tl⋯[Pt⋯Tl]n⋯Pt supported by lateral bridging [Pt](μ-CN)[Tl] ligands, [4]4·dioxane is formed by discrete Pt4Tl4 rectangular aggregates stabilized by [Pt](μ-CN)[Tl] and Pt⋯Tl bonds, which are connected by dioxane bridging molecules through Tl⋯O(dioxane) additional contacts. Solid state emissions are redshifted compared with the mononuclear derivatives 1 and 2 and have been assigned, with the support of theoretical calculations on Pt4Tl4 models, to metal-metal'-to-ligand charge transfer (3MM'LCT [d/s σ*(Pt, Tl) → π*(C^N)]) for 3 and mixed 3MM'LCT/3IL for 4. In fluid THF solution, the complexes are not emissive. At 77 K, 3 and 4 exhibit bright emissions attributed to the formation of bimetallic [{Pt(C^N)(C6F5)(CN)}Tl(THF)x], and anionic [Pt(C^N)(C6F5)(CN)]- fragments. Furthermore, both 3 and 4 exhibit a reversible mechanochromism with a red shift of the emissions upon crushing, suggesting some degree of shortening of metal-metal separation. Finally, complex 3 shows solvatochromic behavior with color/luminescence changes by treatment with a drop of MeOH, CH2Cl2, THF or Et2O, with shifts from 583 in 3-MeOH to 639 nm in 3-THF. However, 4 only demonstrates a bathochromic response to MeOH.

Cycloplatinated (II) Complex Based on Isoquinoline Alkaloid Elicits Ferritinophagy-Dependent Ferroptosis in Triple-Negative Breast Cancer Cells

The development and optimization of metal-based anticancer drugs with novel cytotoxic mechanisms have emerged as key strategies to overcome chemotherapeutic resistance and side effects. Agents that simultaneously induce ferroptosis and autophagic death have received extensive attention as potential modalities for cancer therapy. However, only a limited set of drugs or treatment modalities can synergistically induce ferroptosis and autophagic tumor cell death. In this work, we designed and synthesized four new cycloplatinated (II) complexes harboring an isoquinoline alkaloid C∧N ligand. On screening the in vitro activity of these agents, we found that Pt-3 exhibited greater selectivity of cytotoxicity, decreased resistance factors, and improved anticancer activity compared to cisplatin. Furthermore, Pt-3, which we demonstrate can initiate potent ferritinophagy-dependent ferroptosis, exhibits less toxic and better therapeutic activity than cisplatin in vivo. Our results identify Pt-3 as a promising candidate or paradigm for further drug development in cancer treatment.

Phenylbenzothiazole-Based Platinum(II) and Diplatinum(II) and (III) Complexes with Pyrazolate Groups: Optical Properties and Photocatalysis

Based on 2-phenylbenzothiazole (pbt) and 2-(4-dimethylaminophenyl)benzothiazole (Me2N-pbt), mononuclear [Pt(pbt)(R'2-pzH)2]PF6 (R'2-pzH = pzH 1a, 3,5-Me2pzH 1b, 3,5-iPr2pzH 1c) and diplatinum (PtII-PtII) [Pt(pbt)(μ-R'2pz)]2 (R'2-pz = pz 2a, 3,5-Me2pz 2b, 3,5-iPr2pz 2c) and [Pt(Me2N-pbt)(μ-pz)]2 (3a) complexes have been prepared. In the presence of sunlight, 2a and 3a evolve, in CHCl3 solution, to form the PtIII-PtIII complexes [Pt(R-pbt)(μ-pz)Cl]2 (R = H 4a, NMe2 5a). Experimental and computational studies reveal the negligible influence of the pyrazole or pyrazolate ligands on the optical properties of 1a-c and 2a,b, which exhibit a typical 3IL/3MLCT emission, whereas in 2c the emission has some 3MMLCT contribution. 3a displays unusual dual, fluorescence (1ILCT or 1MLCT/1LC), and phosphorescence (3ILCT) emissions depending on the excitation wavelength. The phosphorescence is lost in aerated solutions due to sensitization of 3O2 and formation of 1O2, whose determined quantum yield is also wavelength dependent. The phosphorescence can be reversibly photoinduced (365 nm, ∼ 15 min) in oxygenated THF and DMSO solutions. In 4a and 5a, the lowest electronic transitions (S1-S3) have mixed characters (LMMCT/LXCT/L'XCT 4a and LMMCT/LXCT/ILCT 5a) and they are weakly emissive in rigid media. The 1O2 generation property of complex 3a is successfully used for the photooxidation of p-bromothioanisol showing its potential application toward photocatalysis.

Synthesis of a light-responsive platinum curcumin complex, chemical and biological investigations and delivery to tumor cells by means of polymeric nanoparticles

Platinum-based anticancer drugs are common in chemotherapy, but problems such as systemic toxicity and acquired resistance of some tumors hamper their clinical applications and therapeutic efficacy. It is necessary to synthesize Pt-based drugs and explore strategies to reduce side effects and improve pharmacokinetic profiles. Photo-responsive chemotherapeutics have emerged as an alternative strategy against several cancers, as photoactivation offers spatial selectivity and fewer side effects. Here, we combine chemical synthesis and nanotechnology to create a multifunctional platinum drug delivery system based on the novel metal complex [Pt(ppy)(curc)] (ppy = deprotonated 2-phenylpyridine, curc = deprotonated curcumin)] embodying the naturally occurring bioactive molecule, curcumin. The ultrasonication method coupled with the layer-by-layer technology was employed to produce nanocolloids, which demonstrated a good biocompatibility, higher solubility in aqueous solution, stability, large drug loading, and good biological activity in comparison with the free drug. In vitro release experiments revealed that the polymeric nanoformulation is relatively stable under physiological conditions (pH = 7.4 and 37 °C) but sensitive to acidic environments (pH = 5.6 and 37 °C) which would trigger the release of the loaded drug. Our approach modifies the bioavailability of this Pt-based drug increasing its therapeutic action in terms of both cytotoxic and anti-metastasis effects.

A new family of luminescent [Pt(pbt)2(C6F5)L]n+ (n = 1, 0) complexes: synthesis, optical and cytotoxic studies

Given the widely recognized bioactivity of 2-arylbenzothiazoles against tumor cells, we have designed a new family of luminescent heteroleptic pentafluorophenyl-bis(2-phenylbenzothiazolyl) PtIV derivatives, fac-[Pt(pbt)2(C6F5)L]n+ (n = 1, 0) [L = 4-Mepy 1, 4-pyridylbenzothiazole (pybt) 2, 4,4'-bipyridine (4,4'-bpy) 3, 1,2-bis-(4-pyridyl)ethylene (bpe) 4 (E/Z ratio: 90/10), 1,4-bis-(pyridyl)butadiyne (bpyb) 5, trifluoroacetate (-OCOCF3) 6] and a dinuclear complex [{Pt(pbt)2(C6F5)}2(μ-bpyb)](PF6)27, in which the trans ligand to the metalated C-(pbt) was varied to modify the optical properties and lipophilicity. Their photophysical properties were systematically studied through experimental and theoretical investigations, which were strongly dependent on the identity of the N-bonded ligand. Thus, complexes 1, 3 and 6 display, in different media, emission from the triplet excited states of primarily intraligand 3ILCT nature localized on the pbt ligand, while the emissions of 2, 5 and 7 were ascribed to a mixture of close 3IL'(N donor)/3ILCT(pbt) excited states, as supported by lifetime measurements and theoretical calculations. Irradiation of the initial E/Z mixture of 4 (15 min) led to a steady state composed of roughly 1 : 1.15 (E : Z) and this complex was not emissive at room temperature due to an enhanced intramolecular E to Z isomerization process of the 1,2-bis-(4-pyridyl)ethylene ligand. Complexes 1-3 and 6 showed excellent quantum yields for the generation of singlet oxygen in aerated MeCN solution with the values of ϕ(1O2) ranging from 0.66 to 0.86 using phenalenone as a reference. Cationic complexes 1-3 exhibited remarkable efficacy in the nanomolar range against A549 (lung carcinoma) and HeLa (cervix carcinoma) cell lines with notable selectivity relative to the non-tumorigenic BEAS-2B (bronchial epithelium) cells. In the A549 cell line, the neutral complex 6 showed low cytotoxicity (IC50: 29.40 μM) and high photocytotoxicity (IC50: 5.75) when cells were irradiated with blue light for 15 min. These complexes do not show evidence of DNA interaction.

Luminescent Anionic Cyclometalated Organoplatinum (II) Complexes with Terminal and Bridging Cyanide Ligand: Structural and Photophysical Properties

We present the synthesis and characterization of two series of mononuclear heteroleptic anionic cycloplatinated(II) complexes featuring terminal cyanide ligand Q⁺[Pt(C^N)(p-MeC₆H₄)(CN)]^- [C^N = benzoquinolate (bzq), Q⁺ = K⁺ 1 and NBu₄⁺ 4; 2-phenylpyridinate (ppy), Q⁺ = K⁺ 2 and NBu₄⁺ 5 and 2-(2,4- difluorophenyl)pyridinate (dfppy), Q⁺ = K⁺ 3 and NBu₄⁺ 6] and a series of symmetrical binuclear complexes (NBu₄)[Pt₂(C^N)₂(p-MeC₆H₄)₂(μ-CN)] (C^N = bzq 7, ppy 8, dfppy 9). Compounds 5, 6, and 7-9 were further determined by single-crystal X-ray diffraction. There are no apparent intermolecular Pt···Pt interactions owing to the presence of bulky NBu₄⁺ counterion. Slow crystallization of K[Pt(ppy)(p-MeC₆H₄)(CN)] 2 in acetone/hexane evolves with formation of yellow crystals, which were identified by single-crystal X-ray diffraction methods as the salt complex {[Pt(ppy)(p-MeC₆H₄)(CN)]₂K₃(OCMe₂)₄(μ-OCMe₂)₂}[Pt(ppy)(p-MeC₆H₄)(μ-CN)Pt(ppy)(p-MeC₆H₄)]·2acetone (10), featuring the binuclear anionic unit 8^- neutralized by an hybrid inorganic-organometallic coordination polymer {[Pt(ppy)(p-MeC₆H₄)(CN)]₂K₃(OCMe₂)₄(μ-OCMe₂)₂}⁺. The photophysical properties of all compounds were recorded in powder, polystyrene film, and solution states with a quantum yield up to 21% for 9 in the solid state. All complexes displayed bright emission in rigid media, and for the interpretation of their absorption and emission properties, density functional theory (DFT) and time-dependent DFT calculations were applied.

Antiproliferative activity and DNA binding studies of cyclometalated complexes of platinum(II) containing 2-vinylpyridine

The cytotoxic activity of four cyclometalated platinum(II) complexes [PtMe(vpy)(L)], containing 2-vinylpyridine (vpy) and the phosphine ligands (L) PMe₂Ph (1a), PPh₃ (1b), PMePh₂ (1c), and P(c-Hex)₃ (1d), were evaluated against human breast cancer (MDA-MB-231), human lung cancer (A549), human colon cancer (SW1116), and non-tumor epithelial breast (MCF-10 A) cell lines. The highest activity was found for 1c with IC₅₀ values of 21.10 µM, 23.36 µM, and 12.96 µM, compared to cisplatin, which was 10.12 µM, 47.57 µM, and 19.50 µM against the A549, SW1116, and MDA-MB-231 cell lines, respectively. 1a-d showed a higher selectivity index (SI) than cisplatin. Docking studies confirmed interaction to the DNA minor groove for all complexes. Genotoxicity studies on 1c showed interactions with the genomic content of malignant cells. Compared with cisplatin as a positive control, a slight shift was found in the electrophoresis mobility, which was utilized further to study the direct interaction of 1c with DNA.

Luminescent 2-phenylbenzothiazole cyclometalated PtII and IrIII complexes with chelating P^O ligands

Two series of cyclometalated Pt^II and Ir^III complexes with general formulas [Pt(pbt){PPh₂(R)-κP,O}] (2a-2c) and [Ir(pbt)₂{PPh₂(R)-κP,O}] (3a-3c), where Hpbt is 2-phenylbenzothiazol and PPh₂(R) is a diphenylphosphino donor functionalized deprotonated acid (R = o-C₆H₄CO₂a, o-C₆H₄SO₃b, CH₂CH₂CO₂c) are presented. The structures of 1, 2a-2c, 3a and 3b were confirmed by single X-ray diffraction analyses, and the intermolecular interactions in 2a were studied using Hirshfeld surface analysis and non-covalent interaction (NCI) methods on its X-ray structure. Their photophysical properties were investigated by absorption and emission analyses [CH₂Cl₂, solid (298, 77 K) and doped polystyrene (PS) films], supported by TD-DFT calculations on 1, 2a-2c and 3a. The Pt^II complexes exhibit bright phosphorescence in the region 525-542 nm, ascribed to a mixed ³IL/³MLCT excited state with a predominant ³IL contribution. The Ir^III derivatives (3a-3c) show orange photoluminescence (535-584 nm, 298 K), blue shifted at 77 K (527-560 nm), originated from the admixture of ³IL/³MLCT/³LLCT excited states. Interestingly, the photoluminescence quantum yields of the Pt complexes 2a-2c (ϕ = 46.5-66.5%) in PS films are remarkably higher than those of the corresponding iridium complexes (ϕ = 17.3-32%) and the precursor 1 (ϕ = 17%). The calculated ³MC-³IL/³MLCT energy gap for 2a and 3a accounts for the higher quantum yield of the Pt in relation to the Ir complex.

Efficiently luminescent heteroleptic neutral platinum(II) complexes based on N^O and N^P benzimidazole ligands

A series of new luminescent cycloplatinated(II) complexes (5a-8a and 5b-8b) with formulas Pt(bt)(N^O) and Pt(bt)(N^P) have been synthesized [bt = phenylbenzothiazole, N^O = (2-(1H-benzimidazole)-phenyl)diphenylphosphine oxide derivatives for 1a-4a and N^P = (2-(1H-benzimidazole)-phenyl)diphenylphosphine derivatives for 1b-4b]. The crystal structures of the complexes show distorted square planar geometries around the platinum centers. There are no obvious π-π and Pt-Pt intermolecular interactions in the crystal lattice due to the presence of sterically bulky ancillary ligands. Consequently, these complexes exhibit structured monomeric emissions in the range of 527-540 nm in CH₂Cl₂ solution. The photoluminescent quantum yields of Pt(bt)(N^O) (5a-8a) in CH₂Cl₂ solution at room temperature are higher than those of Pt(bt)(N^P) (5b-8b). The above result is well consistent with the crystal structural characteristics of the complexes. The structured emission with microsecond radiative lifetimes and the result of TD-DFT calculations indicate that the emissions of these complexes are mainly attributed to a mixed ³LC-MLCT state.

Investigation on Optical and Biological Properties of 2-(4-Dimethylaminophenyl)benzothiazole Based Cycloplatinated Complexes

The optical and biological properties of 2-(4-dimethylaminophenyl)benzothiazole cycloplatinated complexes featuring bioactive ligands ([{Pt(Me 2 N-pbt)(C 6 F 5 )}L] [L = Me 2 N-pbtH 1 , p -dpbH (4-(diphenylphosphino)benzoic acid) 2 , o -dpbH (2-(diphenylphosphino)benzoic acid) 3) , [Pt(Me 2 N-pbt)( o -dpb)] 4 ,  [{Pt(Me 2 N-pbt)(C 6 F 5 )} 2 (µ-PR n P)] [PR 4 P = O(CH 2 CH 2 OC(O)C 6 H 4 PPh 2 ) 2 5 , PR 12 P = O{(CH 2 CH 2 O) 3 C(O)C 6 H 4 PPh 2 } 2 6 ] are presented. Complexes 1-6 display 1 ILCT and metal perturbed 3 ILCT dual emissions. The ratio between both bands is excitation dependent, accomplishing warm-white emissions for 2 , 5 and 6 .  The phosphorescent emission is lost in aerated solutions owing to photoinduced electron transfer to 3 O 2 and formation of 1 O 2 , as confirmed in complexes 2 and 4 . They also exhibit photoinduced phosphorescence enhancement in non-degassed DMSO, due to local oxidation of DMSO by sensitized 1 O 2 , which causes a local degassing. Me 2 N-pbtH and the complexes exhibit specific accumulation in the Golgi apparatus although only 2 , 3 and 6 were active against A549 and HeLa cancer cell lines, being 6 highly selective respect to nontumoral cells. The potential photodynamic property of these complexes was demonstrated with complex 4 .

A 2-(benzothiazol-2-yl)-phenolato platinum(II) complex as potential photosensitizer for combating bacterial infections in lung cancer chemotherapy†

Cancer and antibiotic resistance are two global health threats that usually hamper clinical chemotherapeutic efficacy. Particularly for lung cancer, bacterial infections frequently arise thereby complicating the course of cancer treatment. In this sense, three new neutral luminescent cycloplatinated(II) photosensitizers of the type [Pt(dmba)(L)] (dmba = N,N-dimethylbenzylamine-κN,κC; L = 2-(benzo[d]oxazol-2-yl)-phenolato-κN,κO1, 2-(benzo[d]thiazol-2-yl)-phenolato-κN,κO2, and 2-(1-methyl-1H-benzo[d]imidazole-2-yl)phenolato-κN,κO3) have been characterized and developed to potentially eliminate both resistant bacteria and lung cancer cells. The phototherapeutic effects of complex 2 have been evaluated using low doses of blue light irradiation. Complex 2 exerted promising photoactivity against pathogenic Gram-positive bacteria strains of clinical interest, displaying a phototoxic index (PI) of 15 for methicillin-resistant Staphylococcus aureus, one of the major microorganisms predominating lung infections. Likewise, the anticancer activity of 2 was also increased upon light irradiation in human lung A549 cancer cells (PI = 36). Further in vitro experiments with this platinum(II) complex suggest that ROS-generating photodynamic reactions were involved upon light irradiation, thus providing a reasonable mechanism for its dual anticancer and antibacterial activities.

Luminescent cyclometalated platinum(ii) complexes with acyclic diaminocarbene ligands: structural, photophysical and biological properties

Four new cyclometalated Pt(ii) complexes bearing acyclic diaminocarbene (ADC) ligands, [Pt(C^N)Cl{C(NHXyl)(NHR)}] [C^N = 2,6-difluorophenylpyridine (dfppy), phenylquinoline (pq); R = Pr 3a, 4a, CH₂Ph 3b, 4b], were prepared by the nucleophilic attack on the isocyanide [Pt(C^N)Cl(CNXyl)] (C^N = dfppy 1, pq 2) by the corresponding amine RNH₂ (R = Pr, CH₂Ph). Complexes 3 show in their ¹H NMR spectra in CDCl₃ a notable concentration dependence, with a clear variation of the δ_H (NHXyl) signal, suggesting an assembling process implying donor-acceptor NH_XylCl bonding, also supported by 1D-PGSE (Pulse Field Gradient Spin Echo) and 2D-DOSY (Diffusion Ordered Spectroscopy) NMR experiments in solution and X-ray diffraction studies. The intermolecular interactions in compounds 3a and 3b were studied by using Hirshfeld surface analysis and Non-Covalent Interaction (NCI) methods on their X-ray structures. Their photophysical properties were investigated by absorption and emission spectroscopies and also by TD-DFT calculations performed on 3a and 4b. These complexes show green (3) or orange (4) phosphorescence, attributed to a mixed ³IL/³MLCT excited state. The carbene ligand does not affect the emission maxima but it produces an increase of the quantum yields in relation to the isocyanide in the precursors. In fluid solutions, the emission is not concentration-dependent, but the complexes may show aggregation induced emission as detailed for complexes 3a and 4a. In addition, cytotoxicity studies in the human cell lines A549 (lung carcinoma) and HeLa (cervix carcinoma) showed good activity for these complexes and 3a, 3b and 4a exhibit a strong effect on DNA electrophoretic mobility. To the best of our knowledge, compounds 3 and 4 represent the first examples of cycloplatinated complexes bearing acyclic diamino carbenes with antiproliferative properties.

Fluorinated Cycloplatinated(II) Complexes Bearing Bisphosphine Ligands as Potent Anticancer Agents

A family of cationic cycloplatinated(II) complexes [Pt(dfppy)(P^P)]Cl, dfppy = 2-(2,4-difluorophenyl)pyridine, incorporating bisphosphine ligands, P^P = bis(diphenylphosphino)methane (1, dppm), 1,2-bis(diphenylphosphino)ethane (2, dppe) and 1,2-bis(diphenylphosphino)benzene (3, dppbz), was prepared. The complexes were characterized by means of several analytical and spectroscopic methods. These complexes displayed acceptable stability in the biological environments which was confirmed by NMR, HR ESI-MS and UV-vis techniques. The antiproliferative properties of these complexes were evaluated by National Cancer Institute (NCI) at National Institutes of Health (NIH) against 60 different human tumor cell lines such as leukemia, melanoma, lung, colon, brain, ovary, breast, prostate and kidney. These complexes showed higher cytotoxicity than cisplatin against a wide variety of cancer cell lines such as K-562 (leukemia), HOP-92 (lung), HCT-116 (colon), OVCAR-8 (ovarian), PC-3 (prostate), MDA-MB-468 (breast), and melanoma cancer cell lines. Complex 3 as the most potent compound in this study furnished an excellent anti-proliferative activity compared to the cisplatin against Hela, SKOV3, and MCF-7 cancer cell lines. The main mode of the interaction of 1-3 with DNA was also determined using molecular docking studies.

Synthesis carbonic anhydrase enzyme inhibition and antioxidant activity of novel benzothiazole derivatives incorporating glycine, methionine, alanine, and phenylalanine moieties

Thirteen novel benzothiazole derivatives incorporating glycine, methionine, alanine, and phenylalanine were synthesised by facile acylation reactions through benzotriazole or DCC mediated reactions and their structures were identified by 1H-NMR, 13C-NMR, and FT-IR spectroscopic techniques and elemental analysis. The carbonic anhydrase (CA, EC 4.2.1.1) inhibitory activity of the new compounds was assessed against four human (h) isoforms, hCA I, hCA II, hCA V, and hCA XIII. Some of the synthesised compounds showed good in vitro carbonic anhydrase inhibitory properties, with inhibition constants in the micromolar level. The new amino acid benzothiazole conjugates found to be more effective against hCA V and hCA II inhibition. In vitro antioxidant activities of the novel compounds were determined by DPPH method. Most of the synthesised compounds showed moderate to low antioxidant activities compared to the control antioxidant compounds (BHA and α-tocopherol).

trans-Platinum(II) Thionate Complexes: Synthesis, Structural Characterization, and in vitro Biological Assessment as Potent Anticancer Agents

A series of Pt(II) complexes trans-[Pt(PPh2 allyl)2 (κ1 -S-SR)2 ], 1, PPh2 allyl=allyldiphenylphosphine, SR=pyridine-2-thiol (Spy, 1 a), 5-(trifluoromethyl)-pyridine-2-thiol (SpyCF3 -5, 1 b), pyrimidine-2-thiol (SpyN, 1 c), benzothiazole-2-thiol (Sbt, 1 d), benzimidazole-2-thiol (Sbi, 1 e), were synthesized. They were characterized by NMR, HR ESI-MS, and X-ray crystallography. Treatment of human cancer cell lines (A549, SKOV3, MCF-7) with these complexes resulted in promising antitumor effects in comparison with cisplatin. These compounds showed suitable selectivity between tumorigenic and non-tumorigenic (MCF-10 A) cell lines. Analyses of cell cycle progression and apoptosis were conducted for 1 a, the most cytotoxic compound, to screen dose/time response and to study the antiproliferative mechanism. An electrophoresis mobility shift assay was performed to assess the direct interaction of 1 a with DNA and the strong genotoxic ability was indicated through the comet assay method.

A family of readily synthesised phosphorescent platinum(ii) complexes based on tridentate N^N^O-coordinating Schiff-base ligands

Tridentate ligands, easily synthesised by condensation reactions of simple starting materials, can be used to prepare Pt(ii) complexes that are luminescent in solution, emitting in the red or deep-red spectral region, according to the substituents.

Cationic Au(I) complexes with aryl-benzothiazoles and their antibacterial activity

Two cationic Au(I) complexes derived from aryl-benzothiazoles, namely [(PPh₃)Au(pbt)](OTf) (1) and [(PPh₃)Au(qbt)](OTf) (2) (where pbt = 2‑(pyridyl)benzothiazole and qbt = (quinolyl)benzothiazole, and OTf^- = trifluoromethanesulfonate anion), have been synthesized and structurally characterized by X-ray crystallography. Both complexes exhibit strong antibacterial effects against Gram-negative bacteria such as Acinetobacter baumannii and Pseudomonas Aeruginosa. Results of examination of the reactions of 1 and 2 indicate that these cationic Au(I) complexes rapidly cross the bacterial membrane and exert drug action by disrupting cellular function(s) through binding of cytosolic thiol-containing peptides (such as glutathione) and proteins to the highly reactive (PPh₃)Au⁺ intermediate formed upon in situ dissociation of pbt or qbt.

Cycloplatinated(ii) complexes bearing an O,S-heterocyclic ligand: search for anticancer drugs

Cycloplatinated(ii) complexes containing the 2-mercaptopyridine N-oxide ligand were synthesized and characterized spectroscopically. The biological activities of these complexes were also investigated.